Laurion Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Laurion Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-61,458	Closed	-$55.8K	–	352
2025 Q2	$55.8K	Buy	+61,458	New	+$36.5K	﹤0.01%	370
2024 Q1	–	Sell	-433,748	Closed	-$473K	–	577
2023 Q4	$473K	Sell	433,748 -702,723	-62%	-$770K	﹤0.01%	395
2023 Q3	$1.34M	Sell	1,136,471 -829,776	-42%	-$1.13M	0.01%	358
2023 Q2	$2.77M	Sell	1,966,247 -411,693	-17%	-$569K	0.02%	298
2023 Q1	$3.57M	Hold	2,377,940	–	–	0.02%	252
2022 Q4	$2.78M	Hold	2,377,940	–	–	0.01%	295
2022 Q3	$2.69M	Sell	2,377,940 -44,427	-2%	-$65.2K	0.02%	302
2022 Q2	$3.83M	Buy	+2,422,367	New	+$3.19M	0.06%	190
2020 Q3	–	Sell	-12,476	Closed	-$11K	–	1006
2020 Q2	$11K	Buy	+12,476	New	+$11K	﹤0.01%	858
2018 Q2	–	Sell	-200,458	Closed	-$472K	–	1457
2018 Q1	$472K	Buy	+200,458	New	+$470K	﹤0.01%	1022

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Laurion Capital Management's LCTX Position: Q3 2025 in Review

Laurion Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 61,458 shares — an estimated $55.8K sold.

Laurion Capital Management first reported a position in LCTX in Q1 2018 and held it in 10 quarters. The position peaked at $3.83M in Q2 2022. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

Laurion Capital Management reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
Laurion Capital Management sold 61,458 Lineage Cell Therapeutics shares in Q3 2025, an estimated $55.8K.
Laurion Capital Management first reported a position in Lineage Cell Therapeutics in Q1 2018 and held it in 10 quarters.
Laurion Capital Management's Lineage Cell Therapeutics position peaked at $3.83M in Q2 2022.
112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Laurion Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.